drugset / Trial / NCT03760003
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
Timeline
- Start
- 2019-08-13
- Primary completion
- 2021-04-01
- Completion
- 2021-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obefazimod | Small molecule | 25 mg | Oral |
| Subject | Obefazimod | Small molecule | 50 mg | Oral |
| Subject | Obefazimod | Small molecule | 100 mg | Oral |